This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Teemu Junttila, PhD
Principal Scientist, Translational Oncology at Genentech


Dr. Junttila joined Genentech in 2006. Currently his research is focused in developing Genentech’s T cell dependent bispecific (TDB) antibodies and he is responsible of multiple CD3-bispecific molecules in various stages, ranging from early stage research to clinical development.

Agenda Sessions

  • A Biological Rationale for Toxicity Mitigation with CD3 Bispecifics

    On Demand
  • LIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #5: BISPECIFIC ANTIBODIES: NEW APPROACHES AND CASE STUDIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #5 in the Watch On-Demand Sessions Tab prior to this session